Erasca announces clinical progress for naporafenib

Erasca (ERAS) announced clinical progress for naporafenib and preclinical execution across the company’s RAS targeting franchise. Shannon R. Morris, M.D., Ph.D., Erasca’s chief medical officer, said “In totality, these data strengthen our conviction in the ongoing SEACRAFT-2 Phase 3 trial, for which we gained US and European alignment on the regulatory path in patients with NRASm melanoma. We look forward to randomized dose optimization data from Stage 1 of this trial, which is expected in 2025.” Naporafenib Program Update: NRASm melanoma has a high unmet medical need; Promising initial Phase 1b efficacy results in the SEACRAFT-1 melanoma cohort further bolsters rationale for pursuing NRASm melanoma indication; Generally well-tolerated with mostly low-grade adverse events in the majority of patients; Data reinforce potential of ongoing Phase 3 SEACRAFT-2 trial in patients with NRASm melanoma